Home » Stocks » ORPH

Orphazyme A/S (ORPH)

Stock Price: $5.75 USD -2.81 (-32.83%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $5.98 +0.23 (4.00%) May 7, 7:15 PM
Market Cap 209.38M
Revenue (ttm) n/a
Net Income (ttm) -103.81M
Shares Out 34.95M
EPS (ttm) -3.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.75
Previous Close $8.56
Change ($) -2.81
Change (%) -32.83%
Day's Open 6.30
Day's Range 5.75 - 6.62
Day's Volume 142,987
52-Week Range 5.75 - 14.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Orphazyme A/SInvestor news        No. 05/2021Company Registration No. 32266355

1 week ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease catego...

1 month ago - Business Wire

Orphazyme A S (NASDAQ: ORPH) saw its stock plunge on Monday after failing to meet primary and secondary endpoints in a Phase 2/3 trial. The experimental drug, arimoclomol, was being tested in 150 inclus...

1 month ago - Benzinga

Orphazyme (NASDAQ:ORPH) is currently down 30.59% to a price of $8.75. The stock's current volume for the day is 327.17 thousand, which is approximately 5917.33% of its previous 30-day average volume of ...

1 month ago - Benzinga

Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rare dise...

1 month ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                        No. 10/2021                                                                      ...

1 month ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                        No. 09/2021                                                                      ...

1 month ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease catego...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

2 months ago - Business Wire

Orphazyme A/S Company announcement No. 06/2021Company Registration No. 32266355

2 months ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                        No. 05/2021Inside informationCompany Registration No. 32266355

2 months ago - GlobeNewsWire

Orphazyme A/SInvestor news                                                                                                        No. 04/2021                                                             ...

2 months ago - GlobeNewsWire

Orphazyme A/SInvestor news                                                                                                        No. 03/2021                                                             ...

2 months ago - GlobeNewsWire

LONDON--(BUSINESS WIRE)---- $ORPH #COVID--Open Orphan (AIM:ORPH) announced the world's first COVID-19 characterization study has received ethics approval in the UK.

2 months ago - Business Wire

Orphazyme USInvestor news                                                                                                          No. 02/2021

3 months ago - GlobeNewsWire

Copenhagen, Denmark, February 1, 2021 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transac...

3 months ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                        No. 02/2021                                                                      ...

3 months ago - GlobeNewsWire

Orphazyme A/SInvestor news                                                                                                        No. 01/2021                                                             ...

4 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

4 months ago - Business Wire

Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan ...

4 months ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                         No. 72/2020Inside informationCompany Registration No. 32266355

4 months ago - GlobeNewsWire

Global executive team expanding to support growth plans with three U.S.-based leaders

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

Other stocks mentioned: CYTR
5 months ago - Business Wire

­­Orphazyme A/SCompany announcement                                                                                        No. 70/2020                                                                    ...

5 months ago - GlobeNewsWire

Orphazyme A/SCompany announcement                                                                                        No. 67/2020                                                                      ...

6 months ago - GlobeNewsWire

Due to unfortunate timing, Orphazyme listing on NASDAQ did not go smoothly.

7 months ago - Seeking Alpha

Copenhagen, Denmark, October 2, 2020 – Orphazyme A/S (ORPHA; ORPH) (“Orphazyme”), CVR no. 32266355, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of...

7 months ago - GlobeNewsWire

Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the U.S...

Other stocks mentioned: OZYMF
7 months ago - GlobeNewsWire

Orphazyme has filed to raise $100 million in a U.S. IPO.

Other stocks mentioned: OZYMF
7 months ago - Seeking Alpha

Orphazyme A/SCompany announcement                                                                                        No. 50/2020                                                                      ...

Other stocks mentioned: OZYMF
7 months ago - GlobeNewsWire

Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.

Other stocks mentioned: OZYMF
8 months ago - Market Watch

About ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In... [Read more...]

Industry
Pharmaceutical Preparation Manufacturing
IPO Date
Sep 29, 2020
CEO
Kim Stratton
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ORPH
Full Company Profile

Financial Performance

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 224.70% from the latest price.

Price Target
$18.67
(224.70% upside)
Analyst Consensus: Strong Buy